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STUDY PROTOCOL Open Access
Design of a randomized controlled trial of
Internet-based cognitive behavioral therapy
for treatment-induced menopausal
symptoms in breast cancer survivors
Vera Atema1, Marieke van Leeuwen1, Hester S. A. Oldenburg2, Valesca Retèl1,3, Marc van Beurden4,
Myra S. Hunter5 and Neil K. Aaronson1*
Abstract
Background: Menopausal symptoms are common and may be particularly severe in younger women who
undergo treatment-induced menopause. Medications to reduce menopausal symptoms are either contra-indicated
or have bothersome side effects. Previous studies have demonstrated that face-to-face cognitive behavioral therapy
(CBT) is effective in alleviating menopausal symptoms in women with breast cancer. However, compliance with
face-to-face CBT programs can be problematic. A promising approach is to use the Internet to make this form of
CBT more accessible and feasible for patients. This study is evaluating the efficacy and cost-effectiveness of an
Internet-based CBT program, with or without therapist guidance, in alleviating or reducing the severity of
menopausal symptoms.
Methods/design: In a multicenter, randomized controlled trial we are evaluating the efficacy of two Internet-based
CBT programs in alleviating or reducing the impact of menopausal symptoms, and particularly hot flushes and
night sweats, in breast cancer survivors who have experienced a treatment-induced menopause. Secondary
outcomes include sexual functioning, sleep quality, hot flush frequency, psychological distress, health-related quality
of life and cost-effectiveness. We will recruit 248 women who will be randomized to either a therapist guided or a
self-management version of the 6-week Internet-based CBT program, or to a usual care, waiting list control group.
Self-administered questionnaires are completed at baseline (T0), and at 10 weeks (T1) and 24 weeks (T2) post-
randomization.
Discussion: Internet-based CBT is a potentially useful treatment for reducing menopausal symptoms in breast
cancer survivors. This study will provide evidence on the efficacy and cost-effectiveness of such an Internet-based
CBT program, with or without therapist support. If demonstrated to be efficacious and cost-effective, the availability
of such structured supportive intervention programs will be a welcome addition to standard medical treatment
offered to cancer patients with treatment-induced menopause.
Trial registration: The study is retrospectively registered at ClinicalTrials.gov on January 26th 2016 (NCT02672189).
Keywords: Breast cancer, Menopause, Hot flushes, Cognitive behavioral therapy, Internet-based, Self-management,
eHealth, Randomized controlled trial, Cost-effectiveness
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Background
Breast cancer is the most common cancer among
women worldwide, with approximately 1,7 million new
cases reported in 2012 [1]. Due to increasing numbers of
patients with cancer and improving survival rates [2]
more interest and research has focused on health-related
quality of life (HRQOL) of breast cancer survivors,
including treatment-induced menopausal symptoms.
Nearly 30% of all women with breast cancer are premen-
opausal at time of diagnosis [3]. Breast cancer treatment,
including chemotherapy and endocrine treatment induce
premature menopause, either by damaging the ovaries
or altering the uptake of estrogen [4, 5]. Oophorectomy
also results in surgically induced menopause [6, 7].
Premature menopause is a major concern of younger
women undergoing treatment for breast cancer [8]. Pri-
mary menopausal symptoms include hot flushes, night
sweats, vaginal dryness, decreased libido, dysuria and
urinary incontinence. Secondary symptoms include in-
somnia due to night sweats, dyspareunia because of
vaginal dryness, weight gain, and psychological distress
[4, 9, 10]. Among these menopausal symptoms, hot
flushes are considered to be the most disruptive, with
prevalence rates between 63 and 80% in breast cancer
survivors [9, 11–14]. Hot flushes are often more severe
in women who experience treatment-induced meno-
pause, compared to women going through natural
menopause [7, 15, 16]. The exact etiology of hot flushes
is not fully understood. They appear to be the result of a
dysfunction in the thermoregulatory system via the
hypothalamus, due to (natural or treatment-induced)
changes in estrogen levels. Together with changes in the
neurotransmitters serotonin and norepinephrine they
impact the thermoregulatory homeostasis [17–19].
Menopausal symptoms are an important source of mor-
bidity [20] and discomfort [9, 10] in breast cancer patients
and survivors, and they may also adversely affect women’s
sexual functioning and overall HRQOL [8, 21–26]. More-
over, menopausal symptoms are an important reason why
some women discontinue endocrine treatment [27–29].
Many women experiencing treatment-induced menopause
report unmet needs for information about how to manage
menopausal symptoms [30].
Menopausal symptoms can be treated medically by ei-
ther hormone replacement therapy (HRT) or non- hor-
monal treatment modalities including clonidine, selective
serotonin reuptake inhibitors (SSRI’s) and gabapentin [31,
32]. Although highly effective in alleviating menopausal
symptoms, HRT is contra-indicated in women with a his-
tory of breast cancer [33, 34]. Non-hormonal treatments
are moderately effective but have a range of common and
bothersome side-effects [35–39]. Many breast cancer sur-
vivors with treatment-induced menopause prefer non-
medical treatments for their menopausal symptoms [14].
There is increasing evidence that behavioral interven-
tions have a positive impact on symptoms experienced
by women with naturally occurring and treatment-
induced menopause [40–46]. Cognitive behavioral ther-
apy (CBT) is the only type of behavioral intervention
with level 1 efficacy evidence for both women with nat-
urally occurring and treatment-induced menopause. Use
of CBT has been recommended by the North American
Menopause Society [47].
Hunter and colleagues [48] developed a cognitive
model of menopausal hot flushes to explain symptom
perception, cognitive appraisal, and behavioral reactions
to symptoms. Based on this model, they developed a
form of CBT, including relaxation and psycho-education,
that focuses on the relationships between thoughts, feel-
ings and behavior [49]. Their CBT intervention incorpo-
rates information about symptoms, monitoring and
modifying precipitants, relaxation and stress manage-
ment, cognitive restructuring of unhelpful assumptions
and automatic thoughts, and encouraging helpful behav-
ioral strategies [40].
Three randomized controlled trials (RCT’s) have dem-
onstrated the efficacy of this CBT program in reducing
menopausal complaints in women from the general popu-
lation [42] and in women with menopausal symptoms
after breast cancer treatment [43, 44]. In the study of
Ayers and colleagues [42], 140 women from the general
population were randomly assigned to group CBT, guided
self-help CBT or a no treatment control group. Both CBT
groups decreased significantly in hot flush and night sweat
(HF/NS) problem ratings compared to the control group
6 weeks and 6 months after randomization. These findings
in the general population, however, cannot necessarily be
generalized to cancer patients. Women who go through
natural menopause have much greater opportunities to
communicate with and relate to their same-aged peers
who have gone through or are going through menopause.
Cancer patients distinguish themselves from women who
go through natural menopause by the severity of their
symptoms, and the typically younger age at which they ex-
perience treatment-induced menopause.
In the study of Mann et al. [43] 96 breast cancer survi-
vors with problematic menopausal HF/NS were ran-
domly assigned to either group CBT or usual care. In
this study, women who had received CBT had a signifi-
cantly reduced HF/NS problem rating as compared to
the control group at 9 weeks and at 6 months post-
randomization. Our group [44] conducted a 4-group
RCT (the EVA trial) to evaluate the efficacy of group
CBT, physical exercise (PE), or a combination of CBT and
physical exercise in alleviating treatment-induced meno-
pausal symptoms in breast cancer survivors, as compared
to a waiting list control group (WLC) (N = 422). All inter-
vention groups reported a significant decrease in levels of
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endocrine symptoms 12 weeks and 6 months after
randomization, compared to the usual care waiting list
control group. The two groups that included CBT also re-
ported a significant decrease in HF/NS problem rating at
12 weeks and 6 months. However, in the RCT of Duijts
and colleagues, noteworthy problems were observed in
compliance with the group CBT. More than 50% of
women attended less than 4 of the 6 CBT sessions. Many
women reported scheduling conflicts related to work and
child care as the reason for their under-compliance. Per-
protocol analysis suggested that, if compliance rates could
be increased, the intervention would be even more effect-
ive. Many women indicated an interest and willingness to
undergo a CBT program administered via the Internet.
This was viewed as a more flexible alternative to face-to-
face group CBT, and thus is hypothesized to result in in-
creased compliance and increased efficacy of the treat-
ment. Further, two-thirds of breast cancer patients believe
that Internet-based therapy is equally or more likely to re-
sult in improved physical and mental health, as compared
to face-to-face therapy [50].
A cost-effectiveness analysis (CEA) of the EVA-trial
data showed that CBT was likely to be the most cost-
effective intervention, with incremental cost-utility ratios
of €22,502/quality adjusted life year (QALY) for CBT
versus WLC and €28,078/QALY for PE versus WLC
[51]. Providing CBT via an Internet-based platform, ei-
ther in a guided or self-managed format may further in-
crease the cost-effectiveness of this intervention.
There is growing evidence that Internet-based CBT is
an effective method to treat a range of psychosocial prob-
lems in both the general population and in cancer survi-
vors [52–56]. The overall mean effect size of (ES) of
Internet-based therapy is 0.53 which is comparable to the
average ES of traditional face-to-face therapy [57, 58]. In
general, Internet-based interventions with therapist guid-
ance have been found to be more effective then Internet-
based interventions without any therapist guidance [53,
54, 56]. However, self-management interventions have
clear benefits in terms of accessibility and convenience,
and lower costs. For these reasons, increasing attention is
being paid to optimizing self-management variants of
CBT programs and to identifying who may benefit most
from them [59–62]. For example, it has been argued that
self-managed interventions are more effective with moti-
vated patients who have moderate rather than severe
symptoms [63, 64].
Self-managed interventions are often associated with
low compliance rates. However, this can be improved
when the self-management interventions include prior
screening and are part of a ‘closed system’ (i.e. not ac-
cessible without some form of eligibility check) [59–61].
Under such conditions, compliance rates are similar to
those found in face-to face therapy [60]. There is also
evidence that compliance in self-management inter-
ventions can be further increased by the use of re-
minders [65–67].
Current study
This randomized, controlled, multicenter trial, “EVA-
Online”, is designed to evaluate the efficacy and cost-
effectiveness of two Internet-based CBT programs, one
guided and the other self-managed, to reduce or ameli-
orate treatment-induced menopausal symptoms in
women who have had breast cancer. We hypothesize
that women in both Internet-based CBT groups will re-
port a significantly greater reduction in overall levels of
menopausal symptoms and/or HF/NS problem rating
than women in the control group. Secondarily, we
hypothesize that women in both Internet-based CBT
groups will report significantly greater improvement in
sexual functioning, sleep quality, hot flush frequency,
psychological distress and HRQOL than women in the
control group. We will also evaluate the relative efficacy
of self-managed versus guided Internet-based CBT, but
this will be done in a more descriptive manner, given
that the trial is not powered to test these differences for-
mally. We are also investigating, in a more exploratory
manner, the extent to which program compliance serves
as a moderator, and hot flush beliefs and behavior as me-
diators of the treatment effects on the primary outcomes
of interest [68]. Finally, we hypothesize that both internet-
based CBT groups have a higher probability of being cost-
effective compared to the control group. If demonstrated
to be efficacious and cost-effective, the availability of such
structured supportive intervention programs will be a wel-
come addition to standard medical treatment offered to
cancer survivors with treatment-induced menopause.
Methods
In this trial, patients are randomized to one of three
study arms. There are two interventions arms, i.e.
Internet-based guided CBT and Internet-based self-
management CBT, and one waiting list control arm. The
design of the trial and the anticipated flow of the partici-
pants are displayed in Fig. 1. This trial protocol (June
25th, 2015, version 2) has been approved by the Institu-
tional Review Board (IRB) of The Netherlands Cancer
Institute (under number NL 53182.031.15), as well as by
the review boards of all hospitals from which patients
are being recruited. Any important protocol modifica-
tions (not anticipated) will be reported to the IRB and
the trail registration (clinicaltrials.gov).
Study sample
The study sample will be composed of 248 women,
50 years of age or younger at time of diagnosis, with
histologically confirmed primary breast cancer (stages:
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T1 – T4, N0 – N3 and M0). All women will have been
premenopausal at the time of diagnosis, and will have
experienced a treatment-induced menopause due to
(neo) adjuvant chemotherapy and/or hormonal therapy
and/or oophorectomy. In case of treatment-induced
menopause due to (neo) adjuvant chemotherapy or oo-
phorectomy, treatment should have been completed a
minimum of 4 months and a maximum of 5 years prior
to study entry (with the exception of Herceptin use).
Women may currently be receiving adjuvant hormonal
therapy. All women should be disease-free at time of
study entry. Potentially eligible women are screened for
the presence of problematic HF/NS during the past
2 months. They must have experienced at least ten hot
flushes or night sweats during the past week and these
HF/NS should be experienced as problematic (as indi-
cated by an average score of 2 or higher on three items
of the Hot Flush Rating Scale ([69]).
Women are excluded from the study if they lack basic
proficiency in Dutch, have been treated in the past for
another form of cancer (other than basal cell carcin-
oma), have serious overt cognitive or psychiatric prob-
lems that would preclude them from following the
intervention or completing the study questionnaires, or
have no Internet access. Patients participating in concur-
rent studies or rehabilitation programs focused on the
reduction of or coping with menopausal symptoms (i.e.
relaxation, mindfulness, psychoeducation and/or CBT)
are also excluded.
Recruitment and randomization
We are recruiting patients from 13 community and uni-
versity hospitals in the Netherlands. We identify poten-
tially eligible patients through hospital registries and the
database of the Netherlands Cancer Registry. Potentially
eligible patients are sent a personalized letter by their
treating physician informing them about the study and
the Internet-based program. Women are asked to re-
spond to this invitation by returning either a short
screening questionnaire (when there is interest in par-
ticipating), or a postcard indicating reasons for declining
participation. Non-respondents are sent a reminder
2 weeks after the first invitation.
The women who express interest in the study, but do
not meet the eligibility criteria receive a personalized
letter that explains why they are not eligible. When ini-
tial eligibility criteria are met, women are contacted by
telephone to confirm their eligibility, to explain the
Internet-based program and the RCT, and to confirm
their willingness to invest the requisite time and effort if
they are randomized to either of the two intervention
groups. A baseline questionnaire and informed consent
form are sent to eligible and motivated patients. Upon
return of both to the study staff, patients are randomized
to the guided Internet-based CBT group (n = 83) the
self-management Internet-based CBT group (n = 83) or
to a usual care, ‘waiting-list’ control group (n = 82) using
the minimization technique [70] with age (<40 years;
40–45 years, >45 years), current endocrine treatment for
Fig. 1 Overview of the overall trial design
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breast cancer (yes; no), time since chemotherapy
(<1 year; 1–3 years; > 3 years) and current use of non-
hormonal treatments for hot flushes (antidepressants,
clonidine, gabapentin) (yes; no) as stratification variables.
Due to the nature of the study, blinding is not possible.
Study arms
All participants randomized to either of the two inter-
vention groups receive access to the same Internet-based
CBT program. The primary focus of the program is on
HF/NS, with participants being encouraged to develop
helpful cognitive and behavioral coping styles. Other
problem areas, including sexuality, weight gain and
stress are also addressed by the program. The CBT pro-
gram, is based on the work of Hunter and colleagues
[40, 42, 49, 71] and has been tailored for use by breast
cancer survivors [43, 44]. The program consists of six
modules, which preferably should be followed in six con-
secutive weeks (for a description of the program see
Table 1). Each module contains the following sections:
reflection on progress in past week, an introduction,
psycho-education, and in-session and homework assign-
ments. Video clips of experts (a breast surgeon and a
sexologist) provide complementary information to that
presented in the written text. Also incorporated in the
program are testimonials (short video clips and written
text) of women who have gone through treatment-
induced menopause and who have followed the pro-
gram. The written text also provides examples of how to
complete the homework assignments. The six modules
are presented in a sequential order, wherein each mod-
ule builds upon the previous one. The average estimated
time investment is 1 h a week to complete a module and
30 min per day for homework (e.g. keeping a daily hot
flush/night sweats diary and relaxation exercises).
Intervention group: guided Internet based CBT program
The women in the guided Internet-based CBT group re-
ceive, in addition to the online CBT program, a scheduled
30 min telephone interview prior to the start of the pro-
gram and weekly feedback per email during the course of
the program. After receiving and reading the weekly feed-
back, participants are given access to the next module.
The interview and weekly feedback are provided by a
trained therapist (medical social worker or psychologist).
The therapist has access to the participants’ in-session
Table 1 Description of Program Modules
Module 1 Welcome ▪ Introduction to the online program
▪ Psycho-education about the effect of breast cancer on menopause, menopausal symptoms and the
influence of relaxation.
▪ In-session assignment: making a schedule for reading the sessions and doing homework
▪ Homework: keeping a hot flushes and night sweats diary; practicing relaxation techniques
Module 2 Hot flushes ▪ Psycho-education about the physiology of HF/NS and the role of thoughts, feelings and behaviors
▪ In-session assignment: recognizing patterns of and triggers for hot flushes; cognitive restructuring
of unhelpful thoughts
▪ Homework: as before +monitoring triggers and applying helpful thoughts
Module 3 From stressing to relaxing ▪ Psycho-education about stress, the relationship between stress and hot flushes, cognitive and
behavioral stress management techniques, relaxation.
▪ In-session assignment: identification of stressful events, usual reaction to stress and goal setting to
reduce stress
▪ Homework: as before + implementation of stress goal
Module 4 Improving sleep ▪ Psycho-education about sleep, sleeping problems and how to improve quality of sleep, cognitive
and behavioral reactions to sleep problems/night sweats.
▪ In-session assignment: sleep hygiene questionnaire, goal setting to improve sleep.
▪ Homework: as before + implementation of sleeping goals
Module 5 My body and sexuality ▪ Psycho-education about sexual problems and weight issues, cognitive and behavioral precipitants
and consequences of sexual problems and weight issues.
▪ In-session assignment: goal setting for sexual problems (if present) and weight issues (if present)
▪ Homework: as before + implementation of goals
Module 6 Keep progressing ▪ Psycho-education about the (benefits of) using an action plan.
▪ In-session assignment: identification of helpful cognitive and/or behavioral strategies as discussed/
learned throughout each module, goal setting for maintenance plan; identification of possible barriers
and how to overcome them.
▪ Homework: as before + implementation of maintenance plan
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reflection, homework assignments and daily hot flush
diary. Participants can also contact the therapist by email
if they have any questions. Monitoring of the integrity of
the intervention is carried out at regular intervals by the
study coordinator.
Intervention group: self-management Internet-based CBT
program
The women in the self-management Internet-based CBT
group have access to the online CBT program as de-
scribed above and receive weekly reminders by email.
Participants in this group have access to the entire CBT
program from time of enrollment forward, but are ad-
vised and encouraged to follow the program using a
weekly schedule for 6 consecutive weeks.
Waiting list control group
Participants in the waiting list control group are offered
the opportunity to follow the CBT program after com-
pletion of the 6-month follow up questionnaire. There
are no other behavioral interventions for menopausal
symptoms available through the participating hospitals,
but women in all groups are asked at the follow-up as-
sessments if they engaged in any other means to reduce
their menopausal symptoms.
Data collection
All trial participants complete a battery of self-report
questionnaires at equivalent points in time: T0 (at
baseline prior to randomization), T1 (10 weeks after
randomization) and T2 (6 months after randomization).
A reminder is sent to participants who do not return the
questionnaire within 1 week. If a woman does not
complete the questionnaire in the week after the reminder,
she is contacted by telephone. Every effort is made to ob-
tain a final post-intervention assessment for patients who
discontinue the intervention. Additionally, all women, in-
cluding those in the control group, are asked if, during the
period of the study, they had engaged in any (other) activ-
ities to alleviate their menopausal symptoms (e.g., contacts
with patient self-help groups, use of Internet resources, al-
ternative remedies, etc.).
Study measures
Sociodemographic and clinical data
The patients’ age, education, marital status, living
situation, work status, weight and height, medication use
(including alternative medications or therapies for meno-
pausal symptoms) and life style variables (e.g. smoking,
physical activity/exercise) are obtained via the baseline
questionnaire. Clinical information, including date of diag-
nosis, tumor characteristics, and treatment history are
abstracted from the patients’ medical records and via self-
report. During the follow up period, participants are asked
if they had resumed menstruation and whether they had
discontinued endocrine treatment, if applicable.
Outcome measures
A detailed description of the outcome measures is pro-
vided in Table 2. Briefly, the primary outcome measures
include standardized self-report questionnaires assessing
hot flushes and night sweats problem rating using the
Hot Flush Problem Rating Scale (HFRS) [69], and overall
levels of menopausal symptoms using the Functional As-
sessment of Cancer Therapy –Endocrine symptom scale
(FACT-ES) [72]. Secondary outcome measures include
standardized self-report questionnaires assessing sexual
functioning (SAQ) [73], sleep quality (GSQS) [74]; hot
flush frequency (HFRS) [69], psychological distress
(HADS) [75, 76] and health-related quality of life (SF-36
Health Survey) [77, 78].
Moderating and process measures
Hot flush beliefs and behaviors
Beliefs about hot flushes and night sweats are considered
moderators of the effect of the CBT program [79]. These
are assessed with the Behavior Short Form HFNS Beliefs
and Behavior Scale, a 16 item scale that includes items
from the Hot Flush Beliefs Scale [80] and the Hot Flush
Behavior Scale [81], (Hunter, personal communication).
Compliance with the intervention
Women are asked to indicate the number of CBT pro-
gram modules they completed, the frequency with which
they did the homework assignments and the total
amount of time (in weeks) that they used the program.
We are also able to monitor the actual use (frequency
and duration) of the online CBT program through log
data. We consider completion of the first three modules
evidence of an acceptable level of program compliance
because these are the modules that specifically focus on
the primary outcomes.
Women who do not complete the intervention are
asked to indicate their reason(s) for discontinuation (e.g.,
lack of motivation, illness, program burden). We assess
general self-efficacy, social support and intention to
complete the program as potential predictors of compli-
ance. General self-efficacy is measured with the General
Self-Efficacy scale from [82]. It includes 10 items (4 point
Likert scale). Social support is assessed by the emotional/
informational support subscale (8 items Cronbach’s alpha
0.96) of the Medical Outcome Study- Social Support Scale
((MOS-SS [83]). Behavioral intention is assessed by three
items (5 point Likert scale) derived from the Theory of
Planned Behavior [84].
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Patients’ evaluation of the intervention program
At T1 (immediate post-intervention), women in both
intervention groups are asked to complete a short ques-
tionnaire about their experience with the Internet-based
CBT program. This will include questions about the
perceived efficacy of and satisfaction with the program,
whether they would suggest any changes to the program,
and if they would recommend it to other women experi-
encing treatment-induced menopausal symptoms. In
addition, in an effort to better understand how the
Table 2 Study outcome measures and corresponding questionnaires
Variable Questionnaire Details
Primary outcomes
Hot flush/Night sweats problem rating HFRS ▪ 3 items (subscale), 10 point scale
▪ Score range: 0–10 (mean scores are used);
higher scores indicate higher problem rating
▪ Time frame: 1 week
▪ Test-retest reliability 0.80
Overall level of menopausal symptoms FACT-ES ▪ 18 items, 4 point Likert scale
▪ Score range: 0–72; higher scores indicate fewer menopausal symptoms
▪ Time frame: 1 week
▪ Cronbach’s alpha: >0.80
Secondary outcomes
Sexual functioning SAQ ▪ 10 items, 4 point Likert scale
▪ Subscales: pleasure; discomfort; habit
▪ Score range: pleasure 0–18 higher scores indicate higher levels of pleasure;
discomfort 0–6 lower scores indicates lower levels of discomfort; habit 0–3;
single item (0 ‘less sexual activity than usual’ to 3 ‘much more sexual activity
than usual’
▪ Time frame: past month
▪ Test-retest kappa: 0.50–0.76
Sleep quality GSQS ▪ 14 items, dichotomous (yes/no) scale
▪ Score range: 0–14; higher scores indicate more sleep problems
▪ Time frame: past month
Hot flush frequency HFRS ▪ 2 items (subscale); open-ended frequency scale
▪ Score range: reported average of HF/NS per week
▪ Time frame: past week
▪ Test-retest reliability 0.80
Psychological distress HADS ▪ 14 items, 4-point Likert scale
▪ Subscales: depression (HADS-D); anxiety (HADS-A)
▪ Score range: total score 0–42; subscale scores 0–21 higher score indicates
more psychological distress
▪ Time frame: past week
▪ Cronbach’s alpha: HADS-D 0.67–0.90; HADS-A 0.68–0.93
Health-related quality of life SF-36 ▪ 36 items, dichotomous and 3- to 6-point Likert scales
▪ Subscales: physical functioning, role limitations due to physical health
problems, bodily pain, social functioning, general mental health, role
limitations due to emotional problems, vitality, general health perceptions
▪ Score range: 0–100; higher score indicates higher levels of functioning/
well-being
▪ Time frame: past week
▪ Cronbach’s alpha: 0.66–0.91 (mean 0.84)
▪ For the cost-effectiveness analysis we will map the SF-36 onto the
EuroQol5D to obtain utilities
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program might be improved, we will conduct telephone
interviews (30 min) after the T2 assessment with women
who indicated on the questionnaire that the intervention
did not have the desired effect and/or gave the interven-
tion a low rating and/or would not recommend the pro-
gram to others.
Cost effectiveness
We will perform a cost-effectiveness analysis (CEA)
using a validated health economic model as developed
for use earlier in the EVA-trial [51]. The cost-
effectiveness of the Internet-based guided CBT versus
the Internet-based self-management CBT versus usual
care will be expressed as: (1) cost per clinically relevant
significant reduction on the problem-rating scale of the
HFRS and (2) cost per QALY gained. A change of at
least two points on the ten-point problem-rating scale of
the HFRS, and of 0.5 SD on the FACT-ES is considered
a relevant improvement [49]. A societal and hospital
perspective from the Netherlands, plus a 5 year time
horizon will be adopted. Future costs and effects will be
discounted at 4 and 1.5%, respectively, according to the
Dutch guidelines. A Markov model will be constructed
with 3 mutually exclusive health states: “menopausal
symptoms”, “reduction in menopausal symptoms”, and
“recurrence”. Using a 6-month cycle length, the model
will simulate the course of events in a hypothetical co-
hort of 1000 breast cancer survivors. The “effectiveness”
part of the cost-effectiveness equation will be based on
the HFRS (1) and SF-6D (2). The SF-6D [85], derived
from the SF-36, will be mapped onto the EuroQol-5D,
which will provide utilities. With the utilities, the SF-6D
allows indirectly generating quality adjusted life years
(QALYs) to be used in cost-effectiveness analysis.
For the direct costs, we will ask all women to report at
T1 and T2 their use of health care services (e.g., GP,
medical specialist, paramedical care etc.), medication use
and workdays lost due to illness. In calculating the inter-
vention costs, we will include the time spent by health
professionals in providing feedback to participants
(where applicable), staff training, administration, and
material costs. Detailed descriptions of the intervention
will be made to identify specific cost items and corre-
sponding volumes of resource use. Subsequently, costs
will be calculated by multiplying unit prices (or appro-
priate tariffs) by volumes of use, following the Dutch
pharmacoeconomics costing guidelines [86].
The indirect costs will be measured by the Friction
cost method, which is the period over which the produc-
tion loss is calculated, i.e. the time that an employer
needs to replace a sick employee. The calculation of the
average labor costs per working day will be based on the
weighted average labor costs of full-time and part-time
employed persons in the Netherlands [87].
Power calculation
The HFRS problem rating scale and the FACT-ES scale
score, assessing endocrine symptoms, are the primary
outcomes on which sample size calculations are based.
With a total sample of 198 women (66 per group), and
under the assumption of no interaction, the study will
have 80% power to detect a 0.5 standard deviation differ-
ence (Cohen’s effect size) with a p value of 0.05 (two
sided test) [88]. We anticipate that this effect size will be
sufficient to demonstrate the efficacy of the interven-
tions, as the CBT group intervention in the EVA-study
yielded effect sizes for the primary outcomes of approxi-
mately 0.5 [44]. We will recruit 248 women into the
study, to allow for an attrition rate of approximately 20%
(i.e. women who discontinue participation in the study
entirely, including failure to complete follow up ques-
tionnaires). Women who discontinue participation in
one of the intervention groups but complete the follow
up assessments will be included in the analysis.
Statistical analysis
All data will be anonymized prior to final data analysis.
The data set will not contain any personal identifiers.
Only study staff will have access to these data.
Analyses will first be performed to evaluate the com-
parability of the intervention groups (guided versus self-
management) and control group at baseline in terms of
sociodemographic and clinical characteristics. ANOVA
tests or appropriate non-parametric statistics will be
used, depending on the level of measurement. If, despite
the stratified randomization procedures, the groups are
found not to be comparable on one more background
variables, those variables will be employed routinely as
covariates in subsequent analyses. Questionnaire scores
will be calculated according to published scoring algo-
rithms. We will compare both intervention groups with
the control group over time using multilevel procedures
with repeated measures, using a restricted maximum
likelihood (REML) solution to model specific contrasts
between groups and follow-up assessment [89]. Within
each multilevel model the control group will be the ref-
erence category. For the analysis of the secondary
outcome measures, appropriate statistical adjustments
will be made for multiple testing. Differences in mean
change scores over time between the intervention
groups and the control group will be accompanied by ef-
fect sizes (ES). These effect sizes will be calculated using
standard statistical procedures. Effect sizes of approxi-
mately 0.5 are considered clinically significant [90]. All
analyses will be conducted on an intention to treat
(ITT) basis. In addition, per-protocol (PP) analyses will
be performed (as a secondary analysis) on patients who
met criteria for minimal compliance with the interven-
tion(s). Supplementary analyses will be carried out in
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which data relating to compliance with the program ele-
ments will be taken into account. Specifically, we will
determine whether the level of compliance is associated
significantly with the change over time in the primary
and secondary outcomes. We will also investigate
whether program effectiveness varies significantly as a
function of changes in hot flush beliefs and behaviors.
Cost-effectiveness analysis
We will use a Markov model to perform an incremental
cost-effectiveness and cost-utility analyses. The cost-
effectiveness ratio is calculated by dividing the difference
between the mean total costs of the intervention and
control groups by the difference in mean primary
clinical effects of the groups [51]. The incremental cost-
utility ratio expresses the additional costs of the inter-
vention per quality-adjusted life year (QALY) gained,
compared to the usual care group.
Modeling statistics
State of the art health economic methods will be applied.
These include the estimation of the degree of uncer-
tainty about each input parameter and the use of prob-
abilistic sensitivity analyses. Parameter values will be
drawn randomly from the assigned distributions, using
Monte Carlo simulation with 10,000 iterations. The de-
gree of uncertainty will be illustrated by using confi-
dence intervals for costs and health effects. Scatter-plots,
confidence ellipses on cost-effectiveness planes and
cost-effectiveness acceptability curves will be presented
[91–93]. We will use the European informal ceiling ra-
tio of €30,000 per QALY [86]. Finally, a Budget Impact
Analysis will be performed from the perspective of the
health care provider.
All study results will be published in peer-reviewed
publications and will result in a Ph.D. thesis. Authorship
eligibility will be based on the Vancouver Protocol [94].
Participating patients will receive a lay summary of the
results.
Discussion
A relatively large percentage of young breast cancer sur-
vivors experience treatment-induced menopausal symp-
toms, with hot flushes being the most common and
severe symptom [9, 11–14]. There is a need for effective
and safe non-medical treatment options for these symp-
toms. Studies show that, both in the general population
and among breast cancer survivors, CBT is an effective
treatment method for alleviating menopausal symptoms
when provided in a group setting or through guided
self-help [42–44, 49]. However, compliance can be prob-
lematic [44]. A promising approach is to make this form
of CBT more accessible and feasible for participants by
administering it via the Internet. In the current trial we
are evaluating the efficacy and cost-effectiveness of
Internet-based CBT in alleviating or reducing menopausal
symptoms and HF/NS problem ratings in younger breast
cancer survivors who experience treatment-induced
menopause. Secondary outcomes include sexual function-
ing, sleep quality HF/NS frequency, psychological distress
and overall HRQOL.
This trial has several notable strengths, including: (1)
the randomized trial design; (2) the multicenter nature
of the trial; (3) the comparison of both intervention
groups with a waiting- list control group; (4) the use of
intention-to-treat analysis; (5) the relatively long-term
follow-up; and (6) the inclusion of a cost-effectiveness
evaluation.
Several limitations of the trial should also be noted.
First, it would be valuable to compare the Internet-based
CBT groups with a face-to-face CBT group in order to
compare compliance, experience and effectiveness. How-
ever, recruitment and follow up proved to be problem-
atic in our previous group CBT trial (EVA-study) [44].
Also we consider it important to first establish the
efficacy of the Internet-based CBT program. Second, we
anticipate that both intervention groups (guided and
self-management) will be effective, in comparison with
the control group. The trial was powered based on the
estimated effects of each of the two Internet-based CBT
interventions in comparison to the control group. It may
also be the case that one of the two CBT programs is
more or less effective than the other. One would hope,
given the additional costs involved, that the guided CBT
program would be more efficacious than the self-
management CBT program. However, if such differences
exist, the magnitude of difference will likely be smaller
than that expected between the CBT programs and the
control group. In order to detect a smaller difference (ef-
fect size) when comparing the two variants of the CBT
program, we would need a substantially larger sample
size [88]. Unfortunately, our budget, both in terms of fi-
nancial resources and time, does not allow us to increase
the sample size. Nevertheless, within the limits of statis-
tical power available to us, we will calculate between
CBT group differences in both efficacy and cost-
effectiveness outcomes. Finally, although women in the
waiting-list control group will not be provided with any
materials or program elements, they might look for
other options themselves. However, we do not anticipate
that this will take place in a structured or systematic
way. In any case, at each assessment point, women are
asked to report any activities that they may have under-
taken to alleviate their menopausal symptoms.
In conclusion, given the rate and severity of treatment-
induced menopausal symptoms in breast cancer survivors,
there is a need for more easily accessible and efficient
CBT interventions for these problems. If demonstrated to
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be efficacious and cost-effective, the availability of such a
structured supportive intervention program will be a wel-
come addition to standard medical treatment offered to
breast cancer survivors. It is anticipated that such a pro-
gram will have direct benefit in terms of symptom relief
and the improvement of patients’ HRQL, while making
more efficient use of health care resources.
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